ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ANTX AN2 Therapeutics Inc

2,45
0,08 (3,38%)
01 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
AN2 Therapeutics Inc ANTX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,08 3,38% 2,45 01:50:01
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,39 2,36 2,445 2,40 2,37
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
28.3.202421:10BWAN2 Therapeutics Reports Fourth Quarter and Full Year 2023..
13.2.202423:11EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12.2.202413:01EDGAR2Form 8-K - Current report
12.2.202412:45BWAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase..
30.1.202422:10BWAN2 Therapeutics to Present at Oppenheimer Healthcare Life..
19.1.202400:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202401:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202422:45EDGAR2Form 144 - Report of proposed sale of securities
02.1.202422:36EDGAR2Form 144 - Report of proposed sale of securities
17.11.202300:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.11.202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202322:10EDGAR2Form 8-K - Current report
09.11.202322:05BWAN2 Therapeutics Reports Third Quarter 2023 Financial..
06.11.202313:00BWAN2 Therapeutics to Present at Upcoming Investor Conferences
18.10.202313:00BWAN2 Therapeutics Signs License Agreement with the University..
11.10.202306:01BWAN2 Therapeutics to Present New Data for Epetraborole at..
04.10.202301:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.10.202322:10EDGAR2Form 144 - Report of proposed sale of securities
29.9.202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.9.202322:11EDGAR2Form 144 - Report of proposed sale of securities
26.9.202313:00BWAN2 Therapeutics Signs Grant Agreement to Discover Novel,..
15.9.202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.9.202314:00EDGAR2Form 8-K - Current report
13.9.202313:00BWAN2 Therapeutics commences Phase 3 Part of Phase 2/3..
08.9.202322:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.8.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.8.202322:14EDGAR2Form 144 - Report of proposed sale of securities
16.8.202322:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16.8.202322:47EDGAR2Form 8-K - Current report
16.8.202304:42BWAN2 Therapeutics Announces Pricing of $70.0 Million..
10.8.202322:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202322:18EDGAR2Form 8-K - Current report
10.8.202322:10BWAN2 Therapeutics Reports Second Quarter 2023 Financial..
25.5.202322:10BWAN2 Therapeutics to Present at Jefferies Healthcare..
11.5.202322:10BWAN2 Therapeutics Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock